XIAP and hepatocellular carcinoma: Our results suggest that IFN-α or combined therapy withSG600-IL-24 inhibited the levels of STAT3 in HCC cell lines, and reduced levels ofdownstream proteins including MMP-2, XIAP, OPN, and VEGF.